Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment

Journal of Bone and Mineral Metabolism

Volumn 22, Issue 6, 2004, Pages 569-576

  Miki, Takami ^a   Nakatsuka, Kiyoshi ^a   Naka, Hiroshi ^a   Masaki, Hideki ^a   Imanishi, Yasuo ^a   Ito, Masako ^b   Inaba, Masaaki ^a   Morii, Hirotoshi ^c   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c AINO UNIVERSITY   (Japan)

Author keywords

Bone histomorphometry; Bone microstructure; Human parathyroid hormone 1 34 (hPTH 1 34); Lumbar bone mineral density (LBMD); Osteoporosis

Indexed keywords

PARATHYROID HORMONE[1-34]; TETRACYCLINE;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MARROW; BONE MINERAL; BONE STRUCTURE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMAN; HUMAN TISSUE; ILIAC CREST; MALE; MORPHOMETRICS; OSSIFICATION; OSTEOMALACIA; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SIDE EFFECT; TISSUE SECTION; TRABECULAR BONE;

AGED; BIOPSY; BONE DENSITY; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; TERIPARATIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 8744278947     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-004-0525-z     Document Type: Article

References (15)

1. Tam CS, Heersche JNM, Murray TM, Parsons JA (1982) Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 110:506-512
2. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalmon S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
3. Fujita T. Effect of human parathyroid hormone (1-34) on senile osteoporosis: early phase 2 studies. (personal communication)
4. Fukunaga M, Ono S, Nishiyama T (1997) Effect of a small dose of human parathyroid hormone (1-34) on bone mass in the lumbar vertebrae in patients with senile osteoporosis (in Japanese). Rinsyou Iyaku 13:3371-3382
5. Fujita T, Inoue T, Morii H, Morita R, Norimatsu H, Orimo H, Takahashi HE, Yamamoto K, Fukunaga M (1999) Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporos Int 9:296-306
6. Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Ohashi Y (1997) A criterion for primary osteoporosis (revised edition. 1996; in Japanese). Nippon Kotsutaishya Gakkai Zasshi (J Jpn Bone Miner Metab Assoc) 14:219-233
7. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Pecker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610
8. Takahashi HE (1997) Handbook of Bone Morphometry, 2nd edn. Nishimura Shoten, Niigata, pp 83-86
9. Ito M, Nakamura T, Matsumoto T, Tsurusaki K, Hayashi K (1998) Analysis of trabecular microarchitecture of human iliac bone using microcomputed tomogaphy in patients with hip arthrosis with or without vertebral fracture. Bone 23:163-169
10. Ministry of Health, Labour and Welfare (1999) Japanese Guidelines for the Evaluation of Agents for Treatment of Osteoporosis, Tokyo
11. Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter P, Loeb G, Rouillon A, Barry S, Evreux JC, Avouac B, Marchandise X (1998) Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVO study. Osteoporos Int 8:4-12
12. Gibbs CJ, Aaron JE, Peacock M (1986) Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. BMJ 10:1227-1229
13. World Health Organization (1998) Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis, Geneva
14. Uzawa T, Hori M, Ejili S, Ozawa H (1995) Comparison of the effects of intermittent and continuous administration of human parathyroid hormone (1-34) on rat bone. Bone 16:477-484
15. Vahle JM, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Ma YL, Nold JB (2002) Changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312-321